Personalized immune cells target advanced sarcoma in major trial
NCT ID NCT07174427
Summary
This study is testing a new personalized cell therapy called TBI-1301 for adults with advanced synovial sarcoma, a rare and aggressive cancer. The treatment involves collecting and modifying a patient's own immune cells to target a specific protein (NY-ESO-1) found on their tumor. The main goal is to see if this approach is safe and effective for patients whose cancer has continued to grow despite standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyusyu University Hospital
RECRUITINGFukuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, 541-8567, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.